Baidu
map

Nat Medicine:研究者提出苦味在肺部作用的新机制

2012-05-19 朱敏生等 《自然-医学》

近日,国际著名杂志Nature Medicine刊登了来自南京大学模式动物研究所,温州医学院,麻省大学医学院等处的研究人员的最新研究成果“Activation of BK channels may not be required for bitter tastant-induced bronchodilation,”,在文章中,研究者针对之前一项关于苦味在肺部作用机制的重要成果,进一步提出了不同的

近日,国际著名杂志Nature Medicine刊登了来自南京大学模式动物研究所,温州医学院,麻省大学医学院等处的研究人员的最新研究成果“Activation of BK channels may not be required for bitter tastant-induced bronchodilation,”,在文章中,研究者针对之前一项关于苦味在肺部作用机制的重要成果,进一步提出了不同的观点,指出BK通道激活也许并不是苦味诱导支气管扩张的必需元素。

文章的通讯作者分别是南京大学朱敏生,以及麻省大学医学院诸葛荣华,其中前者早年毕业于第四军医大学,研究兴趣为在系统生物学水平系统研究平滑肌收缩机制:平滑肌是机体中空器官的主要组成部分,其收缩功能是保证所在器官生理功能的基础。如收缩功能异常,则可引起一系列疾病,如胃肠疾病、心血管异常、支气管哮喘等。

一般认为,哺乳动物具有5种基本味觉,即:酸、甜、苦、咸和鲜(umami)。研究表明,人们之所以能够感受酸、甜、苦、咸、鲜味,是因为在味蕾中存在着这五种味觉受体(taste receptor,TR)。目前为止研究者们已经鉴定到的味觉受体只有鲜味和苦味。

2010年来自马里兰大学医学院的研究人员报道称苦味受体不仅存在于口腔中,还存在于人的肺中,他们发现肺中的味觉受体与舌头上的受体结构完全相同,然而在功能上却存在很大差异。舌头上的味觉受体常成簇集中在味蕾,可将味觉信号直接传送至大脑。而肺内的味觉受体并不会成簇积聚,也不会直接向大脑传送信号,而是对带有苦味的物质产生反应。

研究人员认为苦味能增加细胞内钙离子浓度——达到与支气管收缩药物:组肽和缓激肽(bradykinin,BK)产生的水平,但会引发明显的支气管扩张,这说明增加了的钙离子浓度会抑制收缩,这与之前的经典钙离子依赖机制相悖,也就是说通常假设平滑肌中钙离子增高会引起肌肉收缩,而这项研究发现苦味化合物可提升钙离子浓度,却以一种独特的方式负气管肌肉放松。

为了解释这个问题,研究人员提出苦味能产生局部钙离子事件,并且苦味诱导的肌肉放松,以及极化可以通过大电导钙依赖性钾通道(large-conductance Ca2+-activated K+),即BK通道拮抗剂iberiotoxin 被抑制。因此他们认为苦味诱导的支气管扩张,是由于其局部钙离子信号的原因,这一信号能开启BK通道,使得细胞膜极化。

但是这一涉及BK通道激活的观点,只是基于iberiotoxin在苦味诱导的肌肉放松的作用,以及电压敏感染料指示的细胞膜电位。在最新研究中,研究人员认为BK通道活性与肌肉放松之间的关联,并未得到直接证明,这提出了关于肌肉放松机制的疑问。

因此研究人员进一步分析了在BK通道激活方面的苦味作用,并在小鼠气道平滑肌中,分析了多重BK通道的肌肉放松作用,最终发现BK通道激活也许并不是苦味诱导支气管扩张所必需的元素。

研究人员提出一些苦味化合物可与人类和小鼠气管平滑肌细胞作用,所有的苦味化合物都可打开气道,其效应甚至强于那些用于治疗哮喘或慢性阻塞性肺疾患的药物。因此可以用于开发出一些治疗哮喘、肺气肿或慢性支气管炎的新药。这些新药将有可能替换或促进正在使用的药物,这是一种完全不同的新的治疗方法。

doi:10.1038/nm.2733
PMC:
PMID:

Activation of BK channels may not be required for bitter tastant–induced bronchodilation

Cheng-Hai Zhang, Chen Chen, Lawrence M Lifshitz, Kevin E Fogarty, Min-Sheng Zhu & Ronghua ZhuGe

Deshpande et al.1 reported that bitter tastants increase intracellular Ca2+ concentration (to similar levels produced by the bronchoconstrictive agonists histamine and bradykinin) yet cause marked bronchodilation. This implies that elevated Ca2+ concentration inhibits contraction, challenging the classic Ca2+-dependent mechanism underlying smooth muscle contraction2, 3. To resolve this apparent paradox, the authors showed that bitter tastants can generate localized Ca2+ events, and that bitter tastant-induced relaxation and hyperpolarization can be inhibited by the large-conductance Ca2+-activated K+ (BK) channel antagonist iberiotoxin1; thus, they propose that bitter tastant–induced bronchodilation results from its ability to generate localized Ca2+ signals, which in turn open BK channels and hyperpolarize the membrane. However, their assertion of the involvement of BK channel activation was solely based on the effect of iberiotoxin on bitter tastant–induced relaxation and change in membrane potential as assessed by voltage-sensitive dyes. We are concerned that the association of BK channel activity with relaxation has not been directly examined, raising questions about the proposed relaxation mechanism. We therefore directly studied the effect of bitter tastants on the activity of BK channels and examined the relaxation effect of multiple BK channel inhibitors in mouse airway smooth muscle, the same type of smooth muscle tissue used in Deshpande et al.1.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2099610, encodeId=391e209961073, content=<a href='/topic/show?id=dfe48e02792' target=_blank style='color:#2F92EE;'>#苦味#</a>在肺部作用的新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87027, encryptionId=dfe48e02792, topicName=苦味)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Nov 10 12:16:44 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773427, encodeId=54dc1e734278f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat May 04 08:15:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858556, encodeId=50071858556d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 29 09:15:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879240, encodeId=f4bd18e924076, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 03 23:15:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032688, encodeId=c6792032688f2, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 12 22:15:00 CST 2012, time=2012-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577392, encodeId=18ea15e739214, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605723, encodeId=cf451605e23da, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2022-11-10 lifestar

    #苦味#在肺部作用的新机制

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2099610, encodeId=391e209961073, content=<a href='/topic/show?id=dfe48e02792' target=_blank style='color:#2F92EE;'>#苦味#</a>在肺部作用的新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87027, encryptionId=dfe48e02792, topicName=苦味)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Nov 10 12:16:44 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773427, encodeId=54dc1e734278f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat May 04 08:15:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858556, encodeId=50071858556d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 29 09:15:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879240, encodeId=f4bd18e924076, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 03 23:15:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032688, encodeId=c6792032688f2, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 12 22:15:00 CST 2012, time=2012-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577392, encodeId=18ea15e739214, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605723, encodeId=cf451605e23da, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2013-05-04 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=2099610, encodeId=391e209961073, content=<a href='/topic/show?id=dfe48e02792' target=_blank style='color:#2F92EE;'>#苦味#</a>在肺部作用的新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87027, encryptionId=dfe48e02792, topicName=苦味)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Nov 10 12:16:44 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773427, encodeId=54dc1e734278f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat May 04 08:15:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858556, encodeId=50071858556d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 29 09:15:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879240, encodeId=f4bd18e924076, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 03 23:15:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032688, encodeId=c6792032688f2, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 12 22:15:00 CST 2012, time=2012-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577392, encodeId=18ea15e739214, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605723, encodeId=cf451605e23da, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2012-06-29 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=2099610, encodeId=391e209961073, content=<a href='/topic/show?id=dfe48e02792' target=_blank style='color:#2F92EE;'>#苦味#</a>在肺部作用的新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87027, encryptionId=dfe48e02792, topicName=苦味)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Nov 10 12:16:44 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773427, encodeId=54dc1e734278f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat May 04 08:15:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858556, encodeId=50071858556d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 29 09:15:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879240, encodeId=f4bd18e924076, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 03 23:15:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032688, encodeId=c6792032688f2, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 12 22:15:00 CST 2012, time=2012-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577392, encodeId=18ea15e739214, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605723, encodeId=cf451605e23da, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2013-02-03 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=2099610, encodeId=391e209961073, content=<a href='/topic/show?id=dfe48e02792' target=_blank style='color:#2F92EE;'>#苦味#</a>在肺部作用的新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87027, encryptionId=dfe48e02792, topicName=苦味)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Nov 10 12:16:44 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773427, encodeId=54dc1e734278f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat May 04 08:15:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858556, encodeId=50071858556d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 29 09:15:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879240, encodeId=f4bd18e924076, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 03 23:15:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032688, encodeId=c6792032688f2, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 12 22:15:00 CST 2012, time=2012-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577392, encodeId=18ea15e739214, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605723, encodeId=cf451605e23da, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2012-09-12 stfoxst
  6. [GetPortalCommentsPageByObjectIdResponse(id=2099610, encodeId=391e209961073, content=<a href='/topic/show?id=dfe48e02792' target=_blank style='color:#2F92EE;'>#苦味#</a>在肺部作用的新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87027, encryptionId=dfe48e02792, topicName=苦味)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Nov 10 12:16:44 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773427, encodeId=54dc1e734278f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat May 04 08:15:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858556, encodeId=50071858556d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 29 09:15:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879240, encodeId=f4bd18e924076, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 03 23:15:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032688, encodeId=c6792032688f2, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 12 22:15:00 CST 2012, time=2012-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577392, encodeId=18ea15e739214, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605723, encodeId=cf451605e23da, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2099610, encodeId=391e209961073, content=<a href='/topic/show?id=dfe48e02792' target=_blank style='color:#2F92EE;'>#苦味#</a>在肺部作用的新机制, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87027, encryptionId=dfe48e02792, topicName=苦味)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Nov 10 12:16:44 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773427, encodeId=54dc1e734278f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat May 04 08:15:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858556, encodeId=50071858556d1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 29 09:15:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879240, encodeId=f4bd18e924076, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 03 23:15:00 CST 2013, time=2013-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032688, encodeId=c6792032688f2, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 12 22:15:00 CST 2012, time=2012-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577392, encodeId=18ea15e739214, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605723, encodeId=cf451605e23da, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 21 14:15:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map